Published On: 8/17/2020

TARGET-DERM Real-World Evidence Study Reaches 1,000 Enrolled Participants

Target RWE, an innovative health evidence solutions company generating real-world evidence (RWE) and delivering regulatory-grade data to partners to advance clinical, medical, and commercial outcomes, has announced its TARGET-DERM registry reached 1,000 enrolled participants.

“I am pleased to share that our TARGET-DERM registry has officially reached 1,000 enrolled patients since its launch in 2019,” said Target RWE CEO Neal Bibeau. “Today’s announcement is a testament to the hard work and effort from our dedicated team members and site investigators.”

Target RWE’s active dermatology registry, TARGET-DERM, generates real-world data for several immune-mediated inflammatory skin conditions (IMISCs), currently focusing on patients being managed for atopic dermatitis. Eventually, it will include patients with hidradenitis suppurativa (painful bumps under the skin), alopecia areata (autoimmune-related hair loss), and vitiligo (loss of skin pigment).

“The academic steering committee is thrilled with the progress that this registry study has made in a short time,” said TARGET-DERM Steering Committee Co-Chair, Emma Guttman-Yassky, MD, PhD, professor and vice chair for research in the Department of Dermatology at the Icahn School of Medicine at Mount Sinai Medical Center. “The quality data in TARGET-DERM will continue to move the field forward by informing natural history of atopic dermatitis and other inflammatory skin conditions and the impact of disease on treatment paradigms.”

The TARGET-DERM longitudinal registry captures three years of retrospective record data and five years of prospective record data, upon consent, of both adult and pediatric patients from geographically dispersed academic and community sites across the United States. Target RWE plans to expand its TARGET-DERM participating sites to Europe and Canada soon. The TARGET-DERM real-world data collection includes the following biospecimen samples: whole blood, saliva, serum, and tape strips.

With the first patient enrolled in January 2019, TARGET-DERM is the sixth registry created and sponsored by Target RWE. Additional active Target RWE registries include nonalcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), inflammatory bowel disease (IBD), primary biliary cholangitis (PBC), chronic hepatitis B (HBV), asthma, and COVID-19.